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Human mannose-binding lectin (MBL) recognizes a
wide range of microorganisms and triggers the most
ancient pathway of complement activation. How-
ever, 
 
 
 
5% of individuals lack functional serum
MBL and have not been found to be prone to severe
infections in prospective studies. These data suggest
that human MBL is largely redundant for protec-
tive immunity and may even have been subject to
counter selection because of a deleterious impact.
 
The MBL Connection.
 
Long before human Toll-like
receptors (TLRs) were discovered, other pathogen sensors
had been described in the innate immune system. One
such sensor is mannose-binding lectin (MBL), a member
of the collectin family of proteins, in which collagen
structures are associated with carbohydrate-recognizing
lectin domains (1). The low affinity for sugars of the four to
six individual subunits that make up MBL is compensated
for by the high order multimerization, which generates
functional complexes of sufficient avidity for microorganisms
(2). MBL is a serum protein that binds to a large variety of
sugar moieties expressed by many different microorganisms,
ranging from viruses to parasites (3). MBL can mediate
phagocytosis of microorganisms and induce inflammatory
responses via as yet poorly defined receptors on phagocytes.
MBL also provides a distinct, third pathway of complement
activation, which appears to be the most evolutionarily
ancient (4). Complement activation by MBL requires
MBL-associated serine proteases (MASPs; 5). Upon MBL
binding to carbohydrate-bearing pathogens, MASP-2 is
activated and cleaves the C4 and C2 components of com-
plement. The C4b2a complex in turn exerts C3 convertase
activity, generating opsonic C3b fragments. But what actual
role does human MBL play in host defense?
 
Human MBL2 Diversity.
 
The first clue to the physio-
logical function of MBL was obtained in 1989 (6). Super et
al. (6) found that a syndrome characterized by impaired
yeast opsonization and multiple infections, first reported in
1968 (7), resulted from a lack of functional serum MBL.
The first pathogenic mutation in 
 
MBL2
 
, the gene encoding
MBL (
 
MBL1
 
 is a pseudogene) was found in 1991 (8).
Three common missense mutations, affecting codons 52,
54, and 57 in the first 
 
MBL2
 
 exon encoding the NH
 
2
 
-
terminal part of the collagen helix, have since been found,
and the corresponding alleles were designated D, B, and C,
respectively (A is the wild-type allele for all three positions).
The pathogenic effects of these three coding sequence
mutations involve the impairment of MBL multimeri-
zation, decreasing ligand binding, and resulting in a lack of
complement activation (9). Three common regulatory
mutations were also identified in the 
 
MBL2
 
 promoter and
5
 
  
 
untranslated regions: H/L at position 
 
 
 
550, X/Y at
position 
 
 
 
221, and P/Q at position 
 
 
 
4 (10). The regula-
tory and coding variants are in strong linkage disequilibrium,
with only seven haplotypes defined in human populations
(HYPA, LYQA, LYPA, LXPA, HYPD, LYQC, and
LYPB), and therefore most likely result from founder muta-
tional events (11). Among haplotypes carrying the wild-type
A allele, HYPA results in the production of high amounts
of MBL, whereas LXPA is associated with the most severe
defect in MBL secretion. The frequencies of the seven
haplotypes vary considerably between populations (Fig. 1),
reflecting the respective ages of the founder mutations, the
history of human migrations, and selective environmental
pressures acting on the human genome.
 
MBL Deficiency in Man.
 
We will refer to the 
 
 
 
5%
individuals that are homozygous or compound heterozy-
gous for any of the three missense mutations as “MBL
deficient,”  keeping in mind that this definition under-
estimates the actual number of deficient individuals because
certain regulatory mutations are also detrimental. Clearly,
MBL deficiency is not a primary immunodeficiency in the
classical, Mendelian sense of the term, as its clinical pene-
trance is extremely low. It may, however, have a substantial
impact on protective immunity at the population level, as
susceptibility to many common infectious diseases is under
complex genetic control. A number of hospital-based asso-
ciation studies have indeed suggested that MBL deficiency
is more common in patients with infectious diseases (12,
13). MBL-deficient patients seemed to be more susceptible
not only to severe diseases caused by encapsulated bacteria,
but also to a broad range of viral, fungal, and parasitic
illnesses. However, many of these associations were weak,
preliminary, or contradictory, and await confirmation. For
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example, a case control study suggested that MBL deficiency
was weakly associated with invasive pneumococcal disease
in Britain (14), but another study in Denmark reached a dif-
ferent conclusion (15). Perhaps the most convincing study
dealt with meningococcal infection, showing a greater risk
of invasive disease in MBL-deficient children in both hospi-
tal- and community-based case control studies (16).
 
Prospective Studies.
 
In the first prospective population-
based study reported, MBL-deficient children aged 6–17
mo, but not younger or older children, were found to have
an increased risk of acute, generally benign, respiratory dis-
ease (17). A second population-based longitudinal study,
reported in this issue of the 
 
JEM
 
, deals with over 9,000
adults, with 24 and 8 yr of follow-up information on mor-
bidity and mortality, respectively (18). Remarkably, MBL-
deficient adults displayed neither higher morbidity nor
higher mortality caused by infections than adult controls.
This study does not strictly contradict the former popula-
tion-based study in children (17) or the previous hospital-
based association studies, as it would not have enough
power to detect the impact of MBL deficiency on specific
infectious diseases (12, 13). However, this important study
clearly indicates that MBL deficiency is not a major risk
factor for infectious diseases in adult Scandinavians and this
conclusion can probably be extended to other Caucasians
at least. This is consistent with the observation that the dis-
tributions of the three 
 
MBL2
 
 mutant coding alleles are in
Hardy-Weinberg equilibrium worldwide, indicating that
there is currently no preferential selective pressure on any
genotypic combination.
 
MBL Deficiency in the Mouse.
 
Although human MBL
deficiency was first reported in 1989, the existence of two
functional MBL genes in the mouse, 
 
Mbla
 
 and 
 
Mblc
 
, de-
layed the generation of MBL-deficient animals. MBL-A
knockout mice were found to be resistant to both 
 
Candida
albicans
 
 and 
 
Plasmodium yoelii
 
 (19). Surprisingly, mice lack-
ing MBL-A but with sufficient quantities of MBL-C had
higher survival rates in a septic peritonitis model (20). This
Figure 1. Distribution of the seven MBL haplotypes in different indigenous populations from Africa (Kenya and Mozambique; references 10 and 11),
Europe (Denmark; references 11 and 38), Asia (Japan; reference 39), Australia (reference 40), Greenland (references 10 and 11), and South America
(Argentina; reference 11). Only haplotypes with a frequency  5% are shown (with the actual frequency in brackets). Those carrying a coding sequence
mutation (B, C, or D) are indicated in color, and the functionally deficient haplotype (LXPA) is indicated in italics. Of the three haplotypes encoding
missense mutations, LYQC is typically found in sub-Saharan Africans, HYPD mainly in Caucasians, and LYPB has spread from Europeans to native
Americans via Asian populations following historical migrations, whereas all three of these haplotypes are lacking in indigenous Australian populations
(reference 40). Overall, haplotypes associated with missense (HYPD, LYQC, and LYPB) or regulatory (LXPA) deleterious mutations are very common,
with frequencies exceeding 30% in many areas worldwide. 
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suggests that MBL-A is redundant and may even be detri-
mental to mouse defences. The generation of double
knockout MBL-deficient mice is reported in this issue of
the 
 
JEM
 
 (21). The double knockout mice, but neither of
the two single knockout mice, are susceptible to intrave-
nous inoculation with 
 
Staphylococcus aureus
 
 (21). However,
the susceptibility of MBL-deficient mice to intravenously
injected 
 
S. aureus
 
 is modest: at 48 h, when all MBL-defi-
cient mice had died, half of the wild-type mice had also
died of infection. Moreover, although the dose of 
 
S. aureus
 
used for inoculation was very high, the bacterial load in
most tissues analyzed varied by only about one and a half
orders of magnitude. It would thus be interesting to chal-
lenge MBL-deficient animals with other microorganisms,
including those that seem to threaten MBL-deficient pa-
tients, such as 
 
Neisseiria meningitidis
 
 and 
 
Streptococcus pneumo-
niae
 
, but also, and perhaps more importantly, with natural
rodent-tropic pathogens. In any event, these data indicate
that murine MBL is involved in, and that MBL-A and
MBL-B are mutually redundant for, the control of high in-
oculums of 
 
S. aureus
 
 introduced intravenously.
 
Is There a Contradiction between Mice and Men?
 
The two
papers published in this issue seem to convey contradictory
information (18, 21). This may provide yet another example
of greater redundancy in the human immune system com-
pared with the mouse (22). To mention only a couple of
examples, patients with genetic defects in the IL-12/23–
IFN-
 
  
 
cytokine signaling circuit are particularly susceptible
to infection with 
 
Mycobacteria
 
 and 
 
Salmonella
 
, whereas the
corresponding knockout mice have a much broader pheno-
type (23–25). Likewise, patients deficient in IRAK-4, an es-
sential component of TLR and IL-1 receptor signaling, are
susceptible to only a small subset of pyogenic bacteria, 
 
S. au-
reus
 
 and 
 
S. pneumoniae
 
 in particular, which is at odds with
the requirement of the TLR–Il-1R-IRAK pathway for im-
munity to a broad range of pathogens in mouse (26, 27).
Many factors may account for such discrepancies between
human and mouse studies, largely reflecting the differences
between natural and experimental infections (22). Animals
are generally inoculated with mutants of laboratory strains
derived from human-tropic microbes, whereas humans are
infected by coevolving natural pathogens. Moreover, the
routes of experimental infections often bypass mucosal or
cutaneous immunity, which are known to influence sub-
sequent systemic responses. Finally, the “wild-type” con-
trols of knockout animals are only wild-type at the locus
knocked out in the mutant strain, as their homozygous ge-
nomes carry a variety of mutant genes involved in immu-
nity to infection (28). Susceptibility of the MBL-deficient
mouse may thus partly reflect the inherent limitations of ex-
perimental studies. In the ecosystem of human and micro-
bial life, there is more immunological redundancy and MBL
deficiency is likely to be of less importance.
 
The Impact of MBL Deficiency Is Mild.
 
There is, in fact,
no profound contradiction between the two studies pub-
lished in this issue. In mice and humans, the MBL geno-
type influences the complex (i.e., non-Mendelian) inherit-
ance of protective immunity to infection. For example,
MBL-deficient mice were susceptible to intraperitoneal in-
oculation of 
 
S. aureus
 
 only in the presence of concomitant
neutropenia (21), consistent with the higher risk of infec-
tion in MBL-deficient patients undergoing chemotherapy
in two of three studies (29–31). The susceptibility of MBL-
deficient mice to intravenously inoculated 
 
S. aureus
 
 (21)
suggests, in turn, that human MBL deficiency may favor
staphylococcal septicemia, which occurs in a small fraction
of patients with a transcutaneous intravenous central line.
Patients with MBL deficiency and other well-characterized
immunodeficiencies, such as common variable immune de-
ficiency (32), have a higher risk of infectious diseases. The
impact of MBL deficiency in mice and men is thus very
modest and its phenotypic expression is favored by con-
comitant inherited or acquired risk factors. Further suggest-
ing that the MBL–MASP-2 pathway is largely redundant in
host defense, a common amorphic missense mutation was
recently identified in human 
 
MASP2
 
 (33). More studies are
required to define the contribution of MASP-2 deficiency
to protective immunity in mice and men.
 
Is MBL Deficiency Beneficial?
 
The spread of deleterious
 
MBL2
 
 alleles worldwide suggests in itself that human MBL
is merely a redundant and residual vestige of the most an-
cient pathway of complement activation. A globally neutral,
or to an even lesser extent a mildly beneficial contribution
of MBL to host protection, would not account for the ob-
served frequency of MBL deficiency. Instead, the 
 
MBL2
 
mutations may have exerted a beneficial impact on host de-
fense during certain epidemics (34). Their impact may have
been strong, as amorphic common mutations that do not
markedly impair immunity may even confer a strictly Men-
delian protection against infection. For example, a regula-
tory mutation in the gene encoding the Duffy antigen che-
mokine receptor confers resistance to 
 
Plasmodium vivax
 
 and
accounts for the expansion of the mutant allele in endemic
areas (35). The worldwide expansion of a few 
 
MBL2
 
 mu-
tant alleles thus suggests that MBL is not only redundant for
protective immunity in most circumstances, but also delete-
rious to our species in some circumstances. For example,
MBL may favor autoimmune processes or intracellular in-
fections, such as tuberculosis and leishmaniasis (13, 34).
 
Medical Implications.
 
What are the clinical implications
of 15 yr of research in the field of MBL deficiency? Impor-
tantly, there is currently no reason for clinicians to diagnose
MBL deficiency in individual patients with infectious dis-
eases. However, there is a need to evaluate further the con-
tribution of MBL deficiency to specific infections and to
undertake longitudinal population-based cohort studies in
different regions of the world. This is important because
the possibility of therapeutic use of recombinant MBL has
emerged in recent years (36). There is clearly no rationale
for the use of MBL in patients proficient in this molecule,
but is there even a rationale for giving MBL to MBL-defi-
cient patients? Recombinant MBL is expected to be safe
and nonimmunogenic, but it might favor autoimmune re-
actions and intracellular infections, and possibly elicit anti-
bodies against MBL allotypes. Even if well tolerated, it
would be difficult to identify the patients most likely to 
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benefit from recombinant MBL treatment. There seems to
be no clinical justification and it would not appear eco-
nomically worthwhile to treat children with benign, self-
healing acute respiratory disease with MBL (17). Could
such treatment help MBL-deficient children with more se-
vere infections? Experiments in mice have shown that re-
combinant MBL can efficiently prevent infection (21), but
could it help to the cure infection? In any event, before any
therapeutic trial, human studies are required to define more
accurately the target patients.
 
Conclusion.
 
Human MBL deficiency clearly does not
confer a Mendelian susceptibility to infection on individu-
als. In addition, the worldwide expansion of deleterious
MBL2 haplotypes suggests that these may even have been
beneficial at the population level and that balancing selec-
tion may have acted on this gene throughout its evolution-
ary history. Studies of sequence diversity together with the
definition of linkage disequilibrium levels at this locus
would help to elucidate the underlying genetic and biolog-
ical forces leading to the observed patterns. Nevertheless,
the 
 
MBL2
 
 gene may contribute, in specific circumstances
of impaired immunity, to the complex genetic control of
protective immunity to infection. In most circumstances,
other components of the immune system can compensate
for the lack of MBL. The available prospective data do not
suggest that MBL operates as an “ante-antibody” mecha-
nism throughout life (37). Instead, they suggest that MBL
physiologically plays a minor yet detectable role in children
between 6 and 18 mo of age, who no longer have maternal
antibodies but are not yet able to mount an antibody re-
sponse to the carbohydrate antigens of encapsulated bacte-
ria (6, 17).
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